<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40960418</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1897-9483</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>Polish archives of internal medicine</Title><ISOAbbreviation>Pol Arch Intern Med</ISOAbbreviation></Journal><ArticleTitle>Early use of SGLT2 inhibitors after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">17122</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.20452/pamw.17122</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Acute myocardial infarction (AMI) continues to be a primary cause of post-hospitalization heart failure (HF), severely impacting morbidity, healthcare resource consumption, and mortality rates.</AbstractText><AbstractText Label="OBJECTIVES">This meta-analysis sought to assess the efficacy and safety of the early introduction of SGLT2 inhibitors in patients hospitalized for AMI, irrespective of previous HF or diabetes history.</AbstractText><AbstractText Label="PATIENT AND METHODS">Up until June 10, 2025, a comprehensive search was carried out in six major databases, including randomized controlled trials (RCTs) assessing SGLT2i that were started within 14 days of hospitalization for AMI.</AbstractText><AbstractText Label="RESULTS">Seven randomized controlled trials (n = 11,405) comparing SGLT2i with placebo or standard medical therapy without SGLT2i, with follow-up ranging from 6 to 18 months, were included. The commencement of SGLT2 inhibitors markedly diminished the likelihood of HF hospitalization (OR&#x202f;=&#x202f;0.71; 95%CI: 0.58-0.86; P&#x202f;=&#x202f;0.004). No notable changes were detected in all-cause mortality (OR&#x202f;=&#x202f;1.05; 95%CI: 0.77-1.43), cardiovascular mortality (OR&#x202f;=&#x202f;1.04; 95%CI: 0.83-1.30), major adverse cardiovascular events (MACE) (OR&#x202f;=&#x202f;0.94; 95%CI: 0.85-1.05), recurrent myocardial infarction (OR&#x202f;=&#x202f;1.12; 95%CI: 0.73-1.72), or stroke (OR&#x202f;=&#x202f;0.58; 95%CI: 0.26-1.27).</AbstractText><AbstractText Label="CONCLUSIONS">Early initiation of SGLT2i post-AMI significantly reduces the risk of subsequent HF hospitalization without increasing adverse events. However, no mortality benefit was observed. These findings support the selective use of SGLT2i in post-AMI patients at high risk of HF, while highlighting the need for further large-scale trials to assess long-term outcomes and refine patient selection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kurek</LastName><ForeName>Krzysztof</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Pruc</LastName><ForeName>Micha&#x142;</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sajnaga</LastName><ForeName>Ewa</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Grochowski</LastName><ForeName>Cezary</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Siudak</LastName><ForeName>Zbigniew</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Kubica</LastName><ForeName>Jacek</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Uminska</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Momot</LastName><ForeName>Karol</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Krauz</LastName><ForeName>Kamil</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Mamcarz</LastName><ForeName>Artur</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Szarpak</LastName><ForeName>Lukasz</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Pol Arch Intern Med</MedlineTA><NlmUniqueID>101700960</NlmUniqueID><ISSNLinking>0032-3772</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>17</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>17</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>17</Day><Hour>10</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40960418</ArticleId><ArticleId IdType="doi">10.20452/pamw.17122</ArticleId><ArticleId IdType="pii">17122</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>